|Bid||21.02 x 1800|
|Ask||21.03 x 1300|
|Day's Range||20.94 - 21.38|
|52 Week Range||15.50 - 21.95|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||25.91|
|Forward Dividend & Yield||0.79 (3.69%)|
|1y Target Est||28.27|
Amid charges of corruption by French prosecutors, Japan's Olympic Committee president will step down at the end of his term in June. Justin Solomon reports.
Takeda Pharmaceutical Company Limited (TAK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
A pair of plasma donation centers is headed to the Orlando area with dozens of new jobs. Bannockburn, Illinois-based BioLife Plasma Services LP, a subsidiary of Japanese drug company Takeda Pharmaceutical Co. Ltd., will open its first Orlando location March 23 at 867 Good Homes Road in Orlando. "As the demand for plasma-derived therapies increases, BioLife is expanding throughout the United States to help meet that demand," Melissa Richter, a U.S. field marketing representative for BioLife Plasma Services, told Orlando Business Journal.
Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program
CAMBRIDGE, Mass.-- -- FLEXBUMIN 25% , USP, 25% Solution is indicated for hypovolemia, hypoalbuminemia, , and nephrosis), cardiopulmonary bypass surgery, and hemolytic disease of the newborn . Albumin is not indicated as an intravenous nutrient Takeda received its first FDA approval for the Georgia facility, to manufacture GAMMAGARD LIQUID® 10% Solution, in June ...
Vedolizumab superior to adalimumab in achieving clinical remission and mucosal healing at week 52 in patients with moderately to severely active ulcerative colitis
DALLAS, March 8, 2019 /PRNewswire/ -- National law firm Fears Nachawati is launching an immediate investigation into the popular gout drug Uloric, manufactured by Takeda Pharmaceuticals (TAK), after the U.S. Food and Drug Administration (FDA) issued a boxed warning stemming from the increased risk of death from Uloric use. On Feb. 21, 2019, the FDA concluded that there is an increased risk of death from Uloric (febuxostat) compared to another gout medicine, Zyloprim (allopurinol.) This conclusion is based on the FDA's in-depth review of results from a clinical safety study, which found a higher risk of heart-related deaths when taking Uloric.
OTTAWA , Feb. 28, 2019 /CNW Telbec/ - As part of International Rare Disease Day activities across the country and in collaboration with ten patient associations, Takeda Canada Inc. is privileged to launch a new social media campaign to educate Canadians about the importance of access to early diagnosis, treatment and resources by sharing the compelling stories of patients living with rare diseases. Lori's story began when she was 5 years old.
An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market. The 3rd U.S. Circuit Court of Appeals ruled that a federal court in Delaware had been correct in dismissing the FTC's lawsuit against Shire. Shire was acquired by Takeda Pharmaceutical Co last month.
Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey Rare diseases remain undiagnosed as patients ...
– ADCETRIS in Combination with AVD Demonstrated 29-Percent Reduction in the Risk of Progression, Death or Need for Additional Anticancer T
Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported on Thursday. The finding, published in the journal Science, could have implications for approved and experimental dengue vaccines by Sanofi, Takeda Pharmaceutical, Merck & Co and Brazil's Butantan Institute, they said. It was based on tests of blood samples from a long-running study of nearly 1,500 women in Salvador, a city in northeast Brazil that was hard hit by the Zika epidemic that began in 2015.
“We are excited to be at EAHAD and share the results of PROPEL study. The zero all bleed rates and zero all spontaneous joint bleeds in this study have not been reported previously
Jurors in the federal court in Wilmington, Delaware, reached their verdict on the seventh day of a trial after rejecting Baxalta's argument that the June 2016 patent on the treatment, Adynovate, was invalid. Bayer said the infringement arose from Baxalta's exclusive license agreement with Nektar Therapeutics, a San Francisco-based company that had done research with Bayer and knew about the patent, including through litigation in Germany.
Facing pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They aren’t raising prices to make more money but rather to pay a greater cut to middlemen in the medicine-supply chain. For years, drugmakers justified price increases by saying they needed them to fund research and development of new products. Companies including Novartis AG, Johnson & Johnson and Allergan PLC have raised U.S. list prices on hundreds of drugs this year, while simultaneously saying the average net prices they realize after rebates and discounts aren’t going up by much, are staying flat or even are declining.